Differential nicotinic receptor expression in monkey basal ganglia: Effects of nigrostriatal damage

Neuroscience

Volumn 112, Issue 3, 2002, Pages 619-630

  Quik, M ^a   Polonskaya, Y ^a   McIntosh, J M ^a,b   Kulak, J M ^a  

^a PARKINSON S INSTITUTE   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Autoradiography; Dopamine; Nigrostriatal system; Parkinson's disease; 3 nicotinic receptors; 6 nicotinic receptors

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CONOTOXIN; DOPAMINE TRANSPORTER; EPIBATIDINE; LIGAND; NEUROTOXIN; NICOTINIC RECEPTOR; RECEPTOR SUBTYPE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BRAIN REGION; CELL POPULATION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; EXTRAPYRAMIDAL SYNDROME; FEMALE; MALE; MONKEY; NERVE CELL LESION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ALKALOIDS; ANIMALS; AZOCINES; BASAL GANGLIA; BICYCLO COMPOUNDS, HETEROCYCLIC; BRAIN DISEASES; CAUDATE NUCLEUS; CONOTOXINS; CORPUS STRIATUM; DOPAMINE AGENTS; FEMALE; MALE; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; PUTAMEN; PYRIDINES; QUINOLIZINES; RECEPTORS, NICOTINIC; REFERENCE VALUES; SAIMIRI; SUBSTANTIA NIGRA; TISSUE DISTRIBUTION;

EID: 0037025032     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(02)00106-9     Document Type: Article

References (68)

1. Properties of neuronal nicotinic acetylcholine receptors: Pharmacological characterization and modulation of synaptic function
2. Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys
3. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases
4. Molecular basis of levodopa-induced dyskinesias
5. 3H]WIN 35, 428) in the monkey brain
6. A new alpha-conotoxin which targets alpha3beta2 nicotinic acetylcholine receptors
7. Allosteric mechanisms in normal and pathological nicotinic acetylcholine receptors
8. Electrophysiological actions of nicotine on substantia nigra single units
9. The short-term effect of nicotine chewing gum in patients with Parkinson's disease
10. Nicotinic receptor function: New perspectives from knockout mice
11. Nicotinic receptors in human brain: Topography and pathology
12. Non-amine dopamine transporter probe [(3)H]tropoxene distributes to dopamine-rich regions of monkey brain
13. Spatial organization of patch and matrix compartments in the rat striatum
14. The effects of nicotine on dopamine and DOPAC output from rat striatal tissue
15. Nicotine alone and in combination with L-DOPA methyl ester or the D(2) agonist N-0923 in MPTP-induced chronic hemiparkinsonian monkeys
16. Nicotine may relieve symptoms of Parkinson's disease
17. Ageing and Parkinson's disease: Substantia nigra regional selectivity
18. Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson's disease
19. The anatomy and pigmentation of the human substantia nigra in relation to selective neuronal vulnerability
20. Human neuronal nicotinic receptors
21. Characterization of nicotinic receptor-mediated [3H]dopamine release from synaptosomes prepared from mouse striatum
22. Desensitization of nicotine-stimulated [3H]dopamine release from mouse striatal synaptosomes
23. Levodopa-induced dyskinesias and dopamine-dependent stereotypies: A new hypothesis
24. The nigrostriatal system in Parkinson's disease
25. Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum
26. Regional heterogeneity of dopaminergic deficits in vervet monkey striatum and substantia nigra after methamphetamine exposure
27. Cholinergic stimulation of rostral and caudal substantia nigra pars compacta produces opposite effects on circling behavior and striatal dopamine release measured by brain microdialysis
28. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
29. Effects of smoking in patients with early-onset Parkinson's disease
30. Chronic nicotine treatment partly protects against the 1-methyl-4-phenyl-2,3,6-tetrahydropyridine-induced degeneration of nigrostriatal dopamine neurons in the black mouse
31. Nicotinic receptors in the brain: Correlating physiology with function
32. The effects of nicotine on Parkinson's disease
33. Distinct presynaptic control of dopamine release in striosomal and matrix areas of the cat caudate nucleus
34. Loss of nicotinic receptors in monkey striatum after MPTP treatment is due to a decline in a-conotoxin MII sites
35. Alpha-conotoxin MII blocks nicotine-stimulated dopamine release in rat striatal synaptosomes
36. Human alpha6 AChR subtypes: Subunit composition, assembly, and pharmacological responses
37. Parkinson's disease. First of two parts
38. Parkinson's disease. Second of two parts
39. Altered muscarinic and nicotinic receptor densities in cortical and subcortical brain regions in Parkinson's disease
40. Investigating levodopa-induced dyskinesias in the parkinsonian primate
41. Dopamine-like action of nicotine: Lack of tolerance and reverse tolerance
42. Neuronal nicotinic receptor alpha 6 subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain
43. Involvement of alpha6 nicotinic receptor subunit in nicotine-elicited locomotion, demonstrated by in vivo antisense oligonucleotide infusion
44. Stimulation of nigrostriatal dopamine neurones by nicotine
45. Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: Comparison of naive and chronic nicotine-treated rats
46. Continuous dopamine-receptor stimulation in advanced Parkinson's disease
47. Levodopa motor complications in Parkinson's disease
48. Pathophysiology of the basal ganglia in Parkinson's disease
49. Continuous dopamine-receptor stimulation in early Parkinson's disease
50. The heterogeneity of the mesostriatal dopaminergic system as revealed in normal and parkinsonian monkeys
51. The output organization of the substantia nigra in primate as revealed by a retrograde double labeling method
52. Organization of the basal ganglia: The importance of axonal collateralization
53. Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: Possible index of early neuropathology
54. Differential alterations in nicotinic receptor alpha6 and beta3 subunit messenger RNAs in monkey substantia nigra after nigrostriatal degeneration
55. Localization of nicotinic receptor subunit mRNAs in monkey brain by in situ hybridization
56. 125I-conotoxin MII sites to nigrostriatal damage in monkey
57. Stereoselective nicotine-induced release of dopamine from striatal synaptosomes: Concentration dependence and repetitive stimulation
58. A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease
59. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys
60. Striatal preproenkephalin gene expression is upregulated in acute but not chronic parkinsonian monkeys: Implications for the contribution of the indirect striatopallidal circuit to parkinsonian symptomatology
61. Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys
62. Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: Comparison with levodopa treatment
63. Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP
64. Anatomy of the dopamine system in the basal ganglia
65. Functional alpha6-containing nicotinic receptors are present in chick retina
66. 125I-alpha-conotoxin MII identifies a novel nicotinic acetylcholine receptor population in mouse brain
67. Presynaptic nicotinic ACh receptors